Novartis Pharmaceuticals Corporation

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

Phase 1Recruiting12 people12 Mar 2026clinicaltrials.gov

NCT07387926

Phase 1/2Recruiting50 people4 Feb 2026clinicaltrials.gov

NCT07102628

Phase 3Recruiting300 people4 Aug 2025clinicaltrials.gov

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

CollaboratorPhase 2Recruiting130 people2 May 2025clinicaltrials.gov

NCT06941792

Phase 4Active, not recruiting1,590 people24 Apr 2025clinicaltrials.gov

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

CollaboratorPhase 4Recruiting6,000 people3 Apr 2025clinicaltrials.gov

NCT06813911

Phase 3Recruiting340 people7 Feb 2025clinicaltrials.gov

NCT06597019

Phase 3Recruiting60 people19 Sept 2024clinicaltrials.gov

NCT06597006

Phase 3Recruiting9 people19 Sept 2024clinicaltrials.gov

NCT06501443

Phase 4Recruiting520 people15 Jul 2024clinicaltrials.gov

NCT06431763

Phase 4Completed402 people29 May 2024clinicaltrials.gov

NCT06386419

Phase 4Completed65 people26 Apr 2024clinicaltrials.gov

NCT06372925

Phase 4Active, not recruiting318 people18 Apr 2024clinicaltrials.gov

NCT06249165

CollaboratorPhase 4Active, not recruiting130 people8 Feb 2024clinicaltrials.gov

NCT05888493

Phase 3Active, not recruiting109 people5 Jun 2023clinicaltrials.gov

NCT05888103

Phase 3Completed207 people5 Jun 2023clinicaltrials.gov

NCT05791097

Phase 3Withdrawn0 people30 Mar 2023clinicaltrials.gov

NCT05763875

Phase 3Completed350 people10 Mar 2023clinicaltrials.gov

NCT05682378

Phase 3Recruiting195 people12 Jan 2023clinicaltrials.gov

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Phase 3Active, not recruiting610 people4 May 2022clinicaltrials.gov

APOE and amyloid-tau pathology in cognitively unimpaired older adults

1 Jul 2026api.crossref.org